Latest news

• Boehringer says faldaprevir does well in Asian hepatitis C patients

  Boehringer says faldaprevir does well in Asian hepatitis C patients. Trial success in patients from Korea, Japan and Taiwan. ... Boehringer Ingelheim's second-generation hepatitis C virus protease inhibitor faldaprevir achieved a viral cure rate of

• Boehringer moves interferon-free hep C regimen into phase III

  The combination of two of Boehringer's oral hepatitis C drugs - faldaprevir and BI 207127 - plus ribavirin achieved viral cure rate of up to 85 per cent after just 28 weeks' treatment ... Faldaprevir is a once-daily protease inhibitor while BI 207127 is

• J&J wins FDA panel backing for hepatitis C drug

  Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral cure rates and milder side

• Boehringer launches online education portal for hepatitis C

  The launch of the US-focused HepCRedefined.com site came on the day the pharma company moved its interferon-free hep C regimen, which combines faldaprevir and BI 207127, into phase III trials.